Metacrine (MTCR) and Equillium Mutually Agree to Terminate Definitive Merger Agreement

Metacrine, Inc. (NASDAQ: MTCR) and Equillium, Inc. today announced the mutual termination of their previously announced definitive merger agreement. Metacrine is continuing to evaluate all strategic opportunities.

Additional information regarding the termination of the definitive merger agreement is provided set forth in a Current Report on Form 8-K filed by Metacrine with the U.S. Securities and Exchange Commission today and is available at www.sec.gov and on Metacrine’s website under the heading “Investors.”

You May Also Be Interested In

• Citadel unwinds 80% of Aschenbrenner’s portfolio risk - report
• Real and RE/MAX Holdings receive court approval for merger
• Werewolf Therapeutics to merge with Ambros in $150M private placement